



Australian Government

Department of Health and Ageing Therapeutic Goods Administration

File Number: 2010/013135

Dr Adam Guastella The University of Sydney BMRI 100 Mallett Street Camperdown NSW 2050

CTN Scheme (Drugs): Acknowledgement of New Trial

Your notification to conduct a clinical trial under the Clinical Trial Notification (CTN) Scheme, pursuant to Schedule 5A of Regulation 12 of the Therapeutics Goods Regulations, has been received by the Office of Prescription Medicines (OPM).

Trial Number: 2010/0413 Protocol Number: 12261

Drug(s):

Drug Active Name	Trade Name	Code Name	Strength
Oxytocin	Syntocinon	OT	12IU

It is noted that:

- i. the approval of the goods for this trial was given in accordance with Item 3 of Schedule 5A of the Therapeutic Goods Regulations by the body or organisation conducting the trial at each additional site.
- ii. the representative of the Ethics Committee for each additional site has certified that the Committee is constituted and operates in accordance with the NHMRC "National Statement on Ethical Conduct in Human Research" has considered this clinical trial, and has provided advice to the body or organisation conducting the trial.

The Therapeutic Goods Administration has not carried out an assessment of the quality, safety or efficacy of any drug product in relation to this notification.

Please note that, in the event that the Secretary of the Commonwealth Department of Health and Ageing becomes aware that to undertake or continue the clinical trial would be contrary to the public interest, the Secretary has the authority to direct that use of the drug product(s) for this clinical trial must cease.

A form "CTN Scheme (Drugs): Trial Completion Advice" is enclosed. Please fill out and return this form after the Clinical Trial has completed.

Christine Treloar

Experimental Drugs Section

Office of Prescription Medicines

25 August 2010



Australian Government

Department of Health and Ageing Therapeutic Goods Administration

CTN Scheme (Drugs): Clinical Trial Site List

This document lists all sites acknowledged to date for the following clinical trial:

Sponsor: 14195 - University of Sydney

Protocol Number: 12261

Trial Number: 2010/0413

 Date Acknowledged
 Site Name
 State

 25 August 2010
 University of Sydney, Brain & Mind Institute
 NSW

Address: PO Box 100 Woden ACT 2606 Website: www.tga.gov.au Telephone: 02 6232 8101 Facsimile: 02 6232 8112 ABN 40 939 406 804



Australian Government

Department of Health and Ageing Therapeutic Goods Administration

CTN Scheme (Drugs): Trial Completion Advice

Use this form to notify completion of a trial. Sponsor to complete. (Notification of completion should be made only after the trial has been completed at all sites. It is not necessary to notify completion dates for individual sites.)

The following Clinical Trial has now been completed:

Sponsor: 14195 - University of Sydney

Protocol No: 12261

Trial Number: 2010/0413

Or Fax to (02) 6232 8112

H N	
Date Completed:	
Completion Reason (Select one only):	× 4
Concluded Normally	Premature termination - safety
Insufficient Recruits	Premature termination - other
Directed by HAC Secretary	
Other, please state	
Print Name	Position
Signature	Phone
	Fax
Please mail completed form to:	E 105
Therapeutic Goods Administration	81
P0 Box 100	
Woden ACT 2606	
Attention: EDS, Office of Prescription Medicine	es